Discontinued Operations (Tables)

3 Months Ended

Mar. 31, 2018

Discontinued Operations and Disposal Groups [Abstract]

Discontinued Operations

The following table presents key financial results of the infectious disease business included in “Income (loss) from discontinued operations, net of tax” for the three months ended March 31, 2018 and 2017.

	Three Months Ended March 31,
	2018			2017
	(In thousands)
Net product revenues	$	(26	)	$	6,751
Operating expenses:
Cost of revenue	214			3,575
Research and development	412			11,983
Selling, general and administrative	3,096			22,725
Total operating expenses	3,722			38,283
Loss from operations	(3,748		)	(31,532		)
Gain from sale of business	168,955			—
Other expense, net	(74		)	(120		)
Income (loss) from discontinued operations before income taxes	165,133			(31,652		)
Provision for income taxes	51,148			22
Income (loss) from discontinued operations, net of tax	$	113,985		$	(31,674	)

The significant cash flow items from discontinued operations for the three months ended March 31, 2018 and 2017 were as follows:

	Three months ended March 31,
	2018			2017
	(In thousands)
Amortization from discontinued operations	$	—		$	1,983
Changes in contingent purchase price	—			7,821
Gain on sale of business	(168,955		)	—
Proceeds from sale of business	166,383			—
Payments on contingent purchase price	—			(21,066		)

The following table presents the major classes of assets and liabilities at December 31, 2017 related to the infectious disease business which were reclassified as held for sale:

	December 31,
	2017
	(In thousands)
Assets:
Accounts receivable, net	$	9,595
Inventory	41,412
Other receivables	2,740
Intangibles, net	282,398
Goodwill	55,057
Total assets held for sale	$	391,202
Liabilities:
Accounts payable	$	1,127
Accrued expenses	22,945
Contingent purchase price	35,785
Deferred revenue	723
Total liabilities held for sale	$	60,580